





Riverstone Holdings Limited

2QFY2017 Results Briefing – 4 August 2017



Disclaimer



This presentation may contain forward looking statements that involve risks and uncertainties. Actual future performance, outcomes and results may differ materially from those expressed in forward looking statements as a result of a number of risks, uncertainties and assumptions. Representative examples of these factors include (without limitation) general industry and economic conditions, interest rate trends, cost of capital and capital availability, competition from other companies, shifts in customer demands, customers and partners, changes in operating expenses, including employee wages, benefits and training, governmental and public policy changes and the continued availability of financing in the amounts and the terms necessary to support future business. You are cautioned not to place undue reliance on these presentation and the information contain therein, which are based on current view of management on future events.


Without prejudice to or derogating from the generality of the foregoing, no representation or assurance is given by Riverstone that this presentation contain all information that an investor may require. To the extent permitted by applicable law, Riverstone or its related persons (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) arising from the reliance or use of the information contain in this presentation.

Investors are advised to make their own independent evaluation from this presentation, consider their own individual investment objectives, financial situation and particular needs and consult their own professional and financial advisers as the legal, business, financial, tax and other aspects as investors may regard as relevant.


Agenda




Group
Financial
Highlights for
2QFY2017




Outlook & Key
Challenges






- Revenue increased 36.1% yoy from RM156.7 million for 2QFY2016 to **RM213.2 million** for 2QFY2017
- Net profit was stable at **RM27.1 million** for 2QFY2017 (2QFY2016: RM27.3 million)
- Continues to generate positive operating free cash flow of **RM37.6 million** for 2QFY2017
- Net cash position of **RM85.3 million**
- Declares an interim dividend of 1.30 sen (RM) per share

Growing Revenues




* Annual figures may have some discrepancy due to rounding

Gross Profit & Gross Profit Margin




* Annual figures may have some discrepancy due to rounding

Net Profit & Net Profit Margin




* Annual figures may have some discrepancy due to rounding

Positive Cash Flow Generation From Operating Activities



* Annual figures may have some discrepancy due to rounding

Balance Sheet




Year End 31 Dec	As at 30 Jun 2017 (RM'000)	As at 31 Dec 2016 (RM'000)
Net cash and cash equivalents	113,347	103,195
Total borrowings	28,000	0
Shareholders equity	577,046	554,508
Net assets (RM Sen per share) ¹	77.87	74.82
Return on equity ("ROE") ²	21.0% (1HFY2017)	22.1% (1HFY2016)


¹Based on 741.1 million shares in issue excluding treasury shares as at 30 June 2017 and 31 December 2016 respectively

²Calculated on an annualised basis

Consistent Dividends since IPO



Dividends Declared (RM Sen/Share)~



~Adjusted for the 1:1 bonus shares

Dividend Payout Ratio

1HFY2017	35.6%
FY2016	40.0%
FY2015	37.8%
FY2014	36.0%
FY2013	42.4%
FY2012	49.3%
FY2011	48.4%
FY2010	45.5%
FY2009	55.6% [^]
FY2008	45.2%
FY2007	45.0%
FY2006	28.0%

[^] including a special 1 sen tax-exempt dividend


Agenda



Group
Financial
Highlights for
2QFY2017




Outlook & Key
Challenges



Outlook


- Backed by rising demand for healthcare and cleanroom gloves, Phase 4 expansion revised to add 1.4 billion, instead of 1.0 billion, to total annual production capacity of 7.6 billion by end FY2017
- Phase 4 expansion has begun and first production line to be commissioned in August 2017
- Phase 5 expansion with an additional 1.4 billion pieces to ramp up total annual production capacity to 9.0 billion pieces by end FY2018;
- Phase 6 expansion to add another 1.4 billion pieces by end FY2019 to 10.4 billion pieces in total annual production capacity
- Non-HDD markets for cleanroom gloves as well as US and Japan markets for both cleanroom and healthcare gloves continue to gain traction
- Continue to tap on fast-growing markets for healthcare gloves

*Expanding
annual
production
capacity for
gloves*




**expected*

Key Challenges



Challenges	Actions
Competition	<ul style="list-style-type: none">• Cleanroom: Continue to target new markets and customers• Healthcare: Focus on customised and premium products
Increase in costs such as raw material, labor, and fuel	<ul style="list-style-type: none">• Automation• Improve productivity using Lean Six Sigma• Reduce changeover time by installing an additional line

Investment Merits



Continues to be in expansion mode driven by growth in healthcare glove segment and supported by leadership in cleanroom glove segment


Resilient balance sheet underpinned by continued ability to generate positive operating cash flow

Strong dividend payout


Committed management team

Q & A

Q & A



Thank You!



Media & IR Contacts:

Tok Chong Yap
Director

James Bywater
Consultant

riverstone@financialpr.com.sg

Tel: (65) 6438 2990

Fax: (65) 6438 0064

